Moderna, Inc. Furnishes First Quarter 2026 Financial Results
Summary
Moderna, Inc. reported its first quarter 2026 financial results on May 1, 2026, via Exhibit 99.1. The company posted revenue of $0.4 billion, with approximately 80% from international markets. It reported a GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), which included a $0.9 billion non-recurring litigation settlement charge. * Reiterated plan for up to 10% revenue growth in 2026. * Reiterated plan for GAAP operating expense reductions in 2026, excluding the charge. * Advanced infectious disease portfolio with EU approvals for mNEXSPIKE and mCOMBRIAX. * Initiated Phase 3 clinical study for intismeran autogene.
Why It Matters
Investors should note the significant GAAP net loss of $(1.3) billion in Q1 2026, largely driven by a $0.9 billion non-recurring litigation settlement charge. Despite this, Moderna reiterated its 2026 guidance for up to 10% revenue growth and GAAP operating expense reductions, signaling a focus on future financial improvement.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Friday, May 1, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive